Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments-Reference-Cited by-同舟云学术

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments

Published:2017-05-22 Issue:5 Volume:12 Page:e0177364
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

De Groot S.,Blommestein H. M.,Redekop W. K.,Sleijfer S.,Kiemeney L. A. L. M.,Oosterwijk E.,Uyl-de Groot C. A.

Funder

Netherlands Organisation for Health Research and Development

Pfizer

Roche

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. The price of success: cost-effectiveness of molecularly targeted agents;S Sleijfer;Clin Pharmacol Ther,2009

2. Estimates of cancer incidence and mortality in Europe in 2008;J Ferlay;Eur J Cancer,2010

3. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study;R De Angelis;Lancet Oncol,2014

4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;G Hudes;N Engl J Med,2007

5. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;RJ Motzer;J Clin Oncol,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis;Future Oncology;2019-12

3. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group;Future Oncology;2019-08

4. Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies;Clinical Genitourinary Cancer;2019-02

5. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG);Expert Review of Pharmacoeconomics & Outcomes Research;2018-11-19